Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice

Current Opinion in Oncology
Andre B S KhooJ T Lear

Abstract

We summarize the concept of a locally advanced basal cell carcinoma (laBCC) and present the current consensus definition. We also review the key pieces of primary research undertaken in the past year and how these affect the use of smoothened inhibitors in a clinical setting. Medium term follow-up (30 months) of patients treated with vismodegib shows an improvement in response rates for patients with laBCC. The safety profile of vismodegib demonstrated in the original ERIVANCE study has been replicated in a larger patient cohort in a repeat study. Sonidegib is a new smoothened inhibitor currently under investigation for treatment of laBCC, which demonstrates a comparable safety profile to vismodegib. The side-effects of smoothened inhibitors appear related to both dose and duration of treatment. The durability of response to vismodegib is uncertain, but has been observed to last for over a year following discontinuation of treatment. The understanding of the efficacy and safety of vismodegib has improved since its introduction in 2012. A broadening evidence base supports its use as a valid treatment for laBCC. However, questions remain as to how to integrate its use into existing pathways for treating laBCC and its long-term ef...Continue Reading

References

Aug 27, 2005·The British Journal of Dermatology·B L Diffey, J A A Langtry
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard A GrahamPatricia M Lorusso
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoDaniel D Von Hoff
Jun 8, 2012·The New England Journal of Medicine·Aleksandar SekulicAxel Hauschild
Jun 8, 2012·The New England Journal of Medicine·John T Lear
Mar 16, 2013·The British Journal of Dermatology·F R Ali, J T Lear
Jan 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Margaret McCuskerAxel Hauschild
Feb 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J KimJean Y Tang
Feb 14, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jordi RodonAlain C Mita
Mar 4, 2014·Current Dermatology Reports·Shalini V Mohan, Anne Lynn S Chang
Jul 1, 2014·The British Journal of Dermatology·J DreierR Dummer
May 20, 2015·Journal of the American Academy of Dermatology·Aleksandar SekulicUNKNOWN ERIVANCE BCC investigators

❮ Previous
Next ❯

Software Mentioned

STEVIE

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.